

## Special Issue

# Emerging Roles of Chemokines in Cancer Immunotherapy

### Message from the Guest Editor

Current cancer therapy is progressing with increasing speed thanks to the development of immune checkpoint-targeted therapies. Chemokines are recognised as key regulators of cancers, and control the recruitment of immune cells as well as their interaction with tumour and stromal cells. Depending on their target cell selectivity, chemokines display either pro- or antitumour activities. For this Special Issue, we will capture the fast pace in cancer-related chemokine research. We particularly welcome contributions highlighting current research that goes well beyond prototype chemokine functions. Novel avenues with substantial translational potential include the crosstalk between chemokines and immune checkpoint blockade (ICB) therapy, the induction of resistance to therapy, the modulation of the tumour stroma, and direct effects on tumour cells, including growth, mobilisation, and dissemination. Reflecting these exciting developments, current clinical trials frequently include novel chemokine-targeted agents in combination with standard therapies.

### Guest Editor

Prof. Dr. Bernhard Moser

Institute of Infection & Immunity, Cardiff University School of Medicine,  
Cardiff CF14 4XN, Wales, UK

### Deadline for manuscript submissions

closed (31 December 2021)



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/78892](https://mdpi.com/si/78892)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)